BPC-157 vs Apraglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Body Protection Compound-157, Pentadecapeptide BPC 157
BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.
Also: FE 203799, Once-weekly GLP-2 analog
Apraglutide is a once-weekly GLP-2 analog for short bowel syndrome, originally from VectivBio and now owned by Ironwood Pharmaceuticals. Its phase 3 STARS trial hit its main goal in 2024, but in April 2025 Ironwood said the FDA wanted a confirmatory trial, partly because patients in STARS got less drug exposure than planned due to how doses were prepared and given. That new trial, STARS-2, started in June 2026, so approval is years away (a submission before end of 2029 has been mentioned).
Key Comparison Insights
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Apraglutide has stronger research evidence (Human Trials) compared to BPC-157 (Animal Studies).
Detailed Comparison
| Attribute | BPC-157 | Apraglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The leading hypothesis is that BPC-157 promotes new blood vessel growth by upregulating the VEGFR2 receptor, the same receptor that drives angiogenesis, and by tapping into the nitric oxide system through the Akt-eNOS pathway. Better blood supply to injured tissue would, in theory, speed healing of tendons, muscle, and gut lining. Animal work also points to anti-inflammatory effects and interaction with growth-factor signaling. It is worth being blunt here: these mechanisms are mostly worked out in rodents, and the exact molecular target of BPC-157 has never been definitively pinned down. Treat the pathway story as a well-supported hypothesis, not settled fact. | Like teduglutide and glepaglutide, apraglutide activates GLP-2 receptors in the gut, signaling the intestinal lining to grow and absorb more. It was engineered for very low clearance and high plasma protein binding, which gives it a much longer half-life. In rat studies its IV half-life was about 159 minutes versus 19 for teduglutide and 16 for glepaglutide, and it kept more gut-growth activity when dosed less often. That is the basis for once-weekly dosing in humans. Same class caveat as the others: long-term stimulation of gut tissue growth carries a theoretical polyp and tumor risk that requires monitoring. |
| Common Dosing | 250-500 mcg twice daily 1-2x daily | 2.5-5 mg once weekly by body weight (trial dose) Once weekly |
| Administration | Subcutaneous injection near injury site, or systemic | Subcutaneous injection once weekly |
| Typical Duration | 4-12 weeks in most research protocols | 24-week primary endpoint, with treatment continued to week 48 and beyond in STARS |
| Best Time to Take | Morning and evening (or near injury site timing) | Same day each week (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The preclinical record is genuinely large. A 2025 narrative review in the journal Biomedicines counted hundreds of published animal studies showing BPC-157 accelerating healing across tendon, muscle, bone, gut, liver, and nervous-system injury models. The problem is the human side is nearly empty. That same review found only three published human pilot studies (knee pain injections, bladder injections for interstitial cystitis, and an intravenous safety trial) and concluded BPC-157 should be treated as investigational and not recommended for clinical use until proper trials exist. Pharmacokinetic work in rats and dogs found a very short elimination half-life (under 30 minutes after injection) and rapid breakdown into amino acid fragments, which raises real questions about how oral capsules sold online could deliver an intact peptide. Bottom line: lots of promising animal data, no completed randomized controlled trials in people, and no regulatory approval anywhere. | STARS (NCT04627025) randomized 164 adults with SBS and intestinal failure 2:1 to weekly apraglutide (2.5 mg or 5 mg by body weight) or placebo. Topline results in February 2024: weekly parenteral support volume fell 25.5% versus 12.5% on placebo at week 24 (p=0.001). In stoma patients the gap was bigger (25.6% vs 7.8%), and 43% vs 27.5% gained at least one day a week off IV support. But the colon-in-continuity endpoints missed, and enteral autonomy at week 48 (12.5% vs 7.4%) was not significant. Discontinuation for side effects was low (3.6% vs 1.9%). While preparing the NDA, Ironwood found exposure in STARS was lower than intended because of dose preparation and administration, and in April 2025 said the FDA required a confirmatory trial. STARS-2 is a 24-week, placebo-controlled trial of about 124 patients (NCT07742735), started June 2026. So: a positive phase 3 on paper, with a dosing problem that undercuts confidence, and no approval in sight before the end of the decade. |
Frequently Asked Questions: BPC-157 vs Apraglutide
What is the difference between BPC-157 and Apraglutide?
BPC-157 is a healing peptide that bpc-157 is a synthetic 15-amino-acid peptide (sequence gly-glu-pro-pro-pro-gly-lys-pro-ala-asp-asp-ala-gly-leu-val) based on a fragment of a protective protein found in human gastric juice. it is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. the catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof. Apraglutide is a healing peptide that apraglutide is a once-weekly glp-2 analog for short bowel syndrome, originally from vectivbio and now owned by ironwood pharmaceuticals. its phase 3 stars trial hit its main goal in 2024, but in april 2025 ironwood said the fda wanted a confirmatory trial, partly because patients in stars got less drug exposure than planned due to how doses were prepared and given. that new trial, stars-2, started in june 2026, so approval is years away (a submission before end of 2029 has been mentioned). The main differences lie in their mechanisms of action and clinical applications.
Which is better, BPC-157 or Apraglutide?
Neither is universally "better" - the choice depends on your specific goals. BPC-157 is typically used for healing purposes, while Apraglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can BPC-157 and Apraglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using BPC-157 and Apraglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.